Core Viewpoint - Health 160 (02656) announced the appointment of non-executive director Sun Meng and independent non-executive director Zou Jun as members of the nomination committee under the board, effective from September 29, 2025 [1] Group 1 - The appointment of Sun Meng and Zou Jun is aimed at enhancing the governance structure of the company [1]

執行董事 羅寧政先生 （董事長） 冀翠琳先生 黃浪先生 王立法先生 160 Health International Limited 健 康 160 国际有限公司 （於開曼群島註冊成立之有限公司） 董事名單與其角色和職能 健康160国际有限公司董事（「董事」）會（「董事會」）成員載列如下： | 委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 董事 | | | | | 羅寧政先生 | – | 成員 | 主席 | | 冀翠琳先生 | – | – | – | | 黃浪先生 | – | – | – | | 王立法先生 | – | – | – | | 張如協先生 | 成員 | – | – | | 孫萌女士 | – | – | 成員 | | 鄒鈞先生 | 主席 | 成員 | 成員 | | 徐衛國博士 | 成員 | 主席 | 成員 | | 范明博士 | – | – | 成員 | 中國深圳，2025年9月29日 非執行董事 張如協先生 孫萌女士 獨立非執行董事 鄒鈞先生 徐衛國博士 范明博士 董事會已設立三個委員會。各董事委員會的成員載列如下： ...

健康160国际有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，非執行 董事孫萌女士及獨立非執行董事鄒鈞先生已獲委任為董事會轄下提名委員會（「提 名委員會」）成員，自2025年9月29日起生效。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 160 Health International Limited 健 康 160 国际有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2656） 委任提名委員會成員 董事長、執行董事兼首席執行官 上述委任後，提名委員會由五名成員組成，即羅寧政先生（主席）、孫萌女士、鄒 鈞先生、徐衛國博士及范明博士。 於本公告日期，董事會包括：(i)執行董事羅寧政先生、冀翠琳先生、黃浪先生及 王立法先生；(ii)非執行董事張如協先生及孫萌女士；及(iii)獨立非執行董事鄒鈞 先生、徐衛國博士及范明博士。 承董事會命 健康160国际有限公司 羅寧政先生 香港，2025年9月29日 ...

160 Health International Limited 健 康 160 国际有限公司 Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, 160 Health International Limited (the "Company") is writing to inform you that the Company has adopted electron ...

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, 160 Health International Limited (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to ...

Summary of Key Points Core Viewpoint The article discusses the recent activities on the Hong Kong Stock Exchange (HKEX) from September 15 to September 21, highlighting the number of companies that submitted applications, those that passed hearings, and new listings. Group 1: Companies Submitting Applications - A total of 11 companies submitted applications to the HKEX during the specified period [1] - Notable companies include: - **Meilian Steel Structure (Shanghai) Co., Ltd.**: Ranked third in China's prefabricated steel structure market with a market share of 3.5% [2] - **Hangzhou New Element Pharmaceutical Co., Ltd.**: Focused on developing therapies for metabolic, inflammatory, and cardiovascular diseases [3] - **Jiangsu Zhongrun Solar Technology Co., Ltd.**: Second in global photovoltaic cell manufacturing with a market share of 14.6% [4] - **Beijing Junzheng Integrated Circuit Co., Ltd.**: A leading provider of chips for various high-tech applications [5] - **Shanghai Aike Baifa Biopharmaceutical Technology Co., Ltd.**: Focused on therapies for respiratory and pediatric diseases [7] - **Nuwa Insight Technology Co., Ltd.**: An AI technology company in the insurance sector [8] - **Huaqin Technology Co., Ltd.**: A leading ODM platform for smart products [9] - **Saimite Information Group Co., Ltd.**: A leading provider of intelligent industrial software solutions [10] - **Guangzhou Ruoyu Chen Technology Co., Ltd.**: An e-commerce operation company [11] - **Quantitative Holdings Limited**: Focused on online market operations in the consumer sector [12] - **Hangzhou Xianweida Biotechnology Co., Ltd.**: A biopharmaceutical company nearing commercialization [13] Group 2: Companies Passing Hearings - Two companies successfully passed the listing hearings: - **Shenzhen Xipuni Precision Technology Co., Ltd.**: A designer and manufacturer of gold watch cases and bands [14] - **Xuanzhu Biotechnology Co., Ltd.**: An innovative biopharmaceutical company with multiple drug assets in development [15] Group 3: Companies Launching IPOs - Four companies initiated their IPOs: - **Jingfang Pharmaceutical-B**: Global offering of 89.24 million shares with a net fundraising of approximately HKD 1.67 billion [17] - **Different Group**: Global offering of 10.98 million shares with a price range of HKD 62.01-71.20 [18] - **Chery Automobile**: Global offering of 297 million shares with a price range of HKD 27.75-30.75 [19] - **Zijin Gold International**: Global offering of 349 million shares with a price of HKD 71.59 [20] Group 4: New Listings - Three new stocks were listed: - **Hesai Technology (HK:02525)**: Closed at HKD 234.0 per share, up 9.96% on the first day [20] - **Health 160 (HK:02656)**: Closed at HKD 28.22 per share, up 137.34% on the first day [21] - **Jingfang Pharmaceutical-B (HK:02595)**: Closed at HKD 42.10 per share, up 106.47% on the first day [22]

Group 1: IPO Market Activity - The Hong Kong IPO market has seen a surge in diverse companies, including leaders in digital healthcare and lidar technology, with significant activity from sectors like prefabricated steel structures and photovoltaic cells [2][3] - Health160, China's largest digital healthcare service platform, saw its stock price soar by 137.34% on its debut, covering over 260 cities and connecting 44,600 medical institutions [6] - Hesai Technology, a leader in the lidar sector, achieved a dual listing on both US and Hong Kong exchanges, with a market capitalization exceeding HKD 36 billion on its first day [7][8] Group 2: Companies Approved for IPO - Yuan Chuang Technology has received approval for its mainboard IPO, focusing on the research, production, and sales of rubber tracks for agricultural and engineering machinery, with projected revenues of CNY 1.261 billion in 2022 [4] - New Guangyi, a high-tech enterprise specializing in high-performance functional materials, also received approval for its IPO, with revenues expected to grow from CNY 455 million in 2022 to CNY 657 million in 2024 [5] Group 3: New Listings - Jinfang Pharmaceutical made its debut on the Hong Kong Stock Exchange, with an opening surge of 115.79%, focusing on innovative therapies for tumors and autoimmune diseases [9] - Meilian Steel Structure, a prefabricated steel structure service provider, has refiled for an IPO, reporting a revenue increase of 180% year-on-year for the first half of 2025 [10][11] Group 4: Upcoming IPOs - Zijin Gold International plans to raise approximately USD 3.2 billion through its IPO, potentially becoming the largest IPO since May, coinciding with record-high gold prices [17][18] - Huakin Technology, a leading smart product platform, has submitted its IPO application, reporting a revenue increase of 113.06% year-on-year for the first half of 2025 [12]

Core Viewpoint - Health 160 (02656.HK) announced that it will hold a board meeting on September 29, 2025, to approve the interim report for the six months ending June 30, 2025 [1] Group 1 - The board meeting is scheduled for September 29, 2025 [1] - The purpose of the meeting is to approve the group's interim report [1] - The interim report will cover the six months ending June 30, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 160 Health International Limited 健 康 160 国际有限公司 （於開曼群島註冊成立的有限公司） 香港，2025年9月19日 於本公告日期，董事會包括：(i)執行董事羅寧政先生、冀翠琳先生、黃浪先生及 王立法先生；(ii)非執行董事張如協先生及孫萌女士；及(iii)獨立非執行董事鄒鈞 先生、徐衛國博士及范明博士。 （股份代號：2656） 董事會召開日期 健康160国际有限公司（「本公司」，連同其附屬公司及合併附屬實體，統稱「本集 團」）董事（「董事」）會（「董事會」）謹此宣佈，本公司將於2025年9月29日（星期 一）舉行董事會會議，藉以（其中包括）批准本集團截至2025年6月30日止六個月 之中期報告以供發佈。 承董事會命 健康160国际有限公司 董事長、執行董事兼首席執行官 羅寧政先生 ...

Group 1 - Health 160 International Limited successfully listed on the Hong Kong Stock Exchange, raising approximately HKD 359 million through the issuance of 33.6455 million shares at HKD 11.89 each, with funds allocated for network expansion, R&D, service upgrades, strategic acquisitions, and daily operations [1] - The company has established a comprehensive digital service system covering pre-diagnosis, diagnosis, and post-diagnosis, connecting over 44,600 healthcare institutions, including 14,400 hospitals and 3,430 tertiary hospitals, serving over 55.2 million registered users [3][4] - Health 160's revenue has shown steady growth from RMB 525.6 million in 2022 to RMB 628.6 million in 2023, with Q1 2025 revenue reaching RMB 100.5 million, while adjusted net losses have significantly narrowed [4] Group 2 - The Chinese digital healthcare market is entering a period of explosive growth, with forecasts predicting a market size of RMB 740.1 billion by 2030 and a compound annual growth rate of approximately 22.4% from 2024 to 2030 [6] - Health 160 aims to leverage its successful Shenzhen model to accelerate the nationwide rollout of "160 Cloud Hospital," having established 11 regional operation centers to enhance operational efficiency and provide a one-stop service for online appointments, internet consultations, electronic prescriptions, and drug delivery [4][6]